Harvard Bioscience, Inc. (HBIO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Harvard Bioscience, Inc. (HBIO) is down 9.5% since the beginning of the year. At $6 per share, HBIO is trading 35.6% below its 52-week high of $9. Investors who bought $1,000 worth of HBIO shares 5 years ago would now be looking at an investment worth $83.

Harvard Bioscience, Inc. (HBIO) has returned -9.46% so far this year and 13.88% over the past 12 months. Over the last ten years, HBIO has returned -15.31% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Mar 19, 2001, HBIO's average daily return is +0.05%, while the average monthly return is +0.38%. At this rate, an investment would double in approximately 15.2 years.

Historically, 49% of months were positive and 51% were negative. The best month was Mar 2023 with a return of +48.4%, while the worst month was Feb 2025 at -50.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.

On a daily basis, HBIO closed higher 46% of trading days. The best single day was May 29, 2025 with a return of +135.7%, while the worst single day was Sep 18, 2002 at -52.9%.

Harvard Bioscience, Inc. has an annualized alpha of 4.32%, beta of 0.83, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since March 19, 2001.

• This stock participated in 152.91% of S&P 500 Index downside but only 86.50% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HBIO ranks 51 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Harvard Bioscience, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Harvard Bioscience, Inc. was 97.40%, occurring on May 28, 2025. The portfolio has not yet recovered.

The current Harvard Bioscience, Inc. drawdown is 94.45%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Harvard Bioscience, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Harvard Bioscience, Inc. is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.